Search This Blog

Wednesday, May 6, 2026

Bioventus tops Q1 2026 expectations, raises guidance

 

Bioventus tops Q1 2026 expectations, raises full-year adjusted EPS guidance to $0.75–$0.79 and cash from operations outlook

  • Q1 2026 net income was $3.1 million on revenue of $132.1 million.
  • Management reaffirmed full-year revenue outlook while raising adjusted EPS and cash from operations guidance.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)